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Statins are naturally occurring compounds that inhibit the enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase. 
Through their beneficial management of the body’s lipid metabolism, they are widely used medicinal drugs employed 
extensively in the primary and secondary prevention of cardiovascular disease. In addition, many studies to date have 
shown the therapeutic advantages derived from using statins in conditions such as endometriosis, osteoporosis, 
polycystic ovary syndrome and rheumatic disease. Due to the steady increase of cancer morbidity rates, as dem-
onstrated by epidemiological data, the putative role of statins in treating or preventing cancer has been ever more 
frequently investigated; including for colorectal cancer. This paper attempts to bring together current knowledge/
evidence on statin therapy targeted at the development, disease course and treatment of colorectal cancer, both in 
terms of epidemiological findings and clinical observations. Because of the reported link between metabolic disorders 
and the development of colorectal cancer, particular focus is given to the effects of statins on signalling pathways 
involving insulin-like growth factors (IGFs).
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Introduction
Statin compounds are naturally derived substances 
which have been introduced into medical practice for treat-
ing hypercholesterolemia and are also currently used in 
the primary and secondary prevention of cardiovascular 
disease; they are also regarded as being potentially effective 
for treating osteoporosis, endometriosis, polycystic ovary 
syndrome and rheumatic diseases [1]. The first statin was 
mevastatin, isolated in 1976 from the mould of Penicilum 
Citrinum with others being subsequently isolated, (e.g. lo-
vastatin, pravastatin and simvastatin), until which time a 
method for chemical synthesis was developed, leading to 
chemical compounds of similar structure and properties 
such as fluvastatin, atorvastatin, pitavastatin, cerivastatin 
and rosuvastatin (Table I) [2].
These substances are biologically active, in that they 
inhibit the enzyme 3-hydroxy-3-methyl-glutaryl-CoA (HMG-
CoA) reductase, whereby HMG-CoA is not transformed into 
mevalonic acid [3]. Such blocking of the mevalonic pathway 
(Fig. 1) has numerous molecular consequences, described 
in the literature as pleiotropic effects of statins, which in-
clude the following; decreasing the endogenous synthe-
sis of cholesterol coupled with increasing the number of 
LDL receptors on hepatocyte cell surfaces, reducing the 
prenylation of protein, decreased bile acid synthesis and 
their intermediates as well as other steroids (like vitamin D), 
modulating inflammatory responses, affecting adipokines 
release and having fibrinolytic activity [4].
Besides statins, interest in mevalonic pathway inhibitors 
that act further downstream, such as bisphosphonates, 
has increased following the discovery that a mutation in 
p53 protein, as found in many cancers, causes significant 
increases of mevalonic acid metabolism in tumour cells 
[5]. Of further importance is the ability of statins to block 
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post-translational prenylation of proteins, including proteins 
of the Rho and Ras family which amongst other things are 
responsible for initiating apoptosis in cancer cells [5, 6]. The 
immunomodulatory effects of statins should be stressed 
which also arise from arresting prenylation. Prenyl pyroph-
osphate activates the Caspase-1 pathway thereby impairing 
production/maturation of active interleukins 1 and 18.
Statin treatment however effectively activates NK cells 
(natural killer), which constitute a first-line of defence 
against cancerous cells [5, 7]. Moreover, simvastatin stimu-
lates production of IL-1, IL-2 and TNF protein by epithelial 
and dendritic cells [7, 8]. Such a plethora of effects, along 
with crossovers between intermediates from the mevalonic 
pathways which activate growth factors (such as IGF, VEGF, 
PDGF), has prompted much research on the role of HMG-
CoA inhibitors in tumourigenesis [9].
In global terms, colorectal cancer is the third most com-
monly occurring cancer in men and the second found in 
women as well as being the fourth most common cause 
of cancer mortality. Since the 1980’s, Poland has witnessed 
a steady rise in its incidence. Colorectal cancer morbidity 
mainly affects those aged over 50 years, where the risk 
increases with age; other epidemiological risk factors being 
diet (i.e. an unhealthy diet with a high, animal-derived fat 
content of animal origin and poor in fibre), the co-existence 
of the metabolic syndrome, cigarette smoking, alcohol 
abuse, and a sedentary lifestyle together with ethnic and 
geographical factors [10].
Epidemiology
Over many years, taking regular statin medication/phar-
macotherapy has been reported as a means for affording 
protection against colonic cancer development along with 
being used in those therapies designed to improve survival 
and treatment outcomes in patients already diagnosed 
with cancer. The beneficial effects of statins has been deter-
mined variously for lovastatin, cerivastatin, simvastatin and 
atorvastatin according to the study, where relative risks of 
contracting colonic cancer has been reduced; ranging from 
around a dozen up to 50% when compared with control 
groups [11–16]. Contemporary observations confirm such 
findings. Broughton et al. performed a retrospective analy-
sis on approximately 200 subjects which found that using 
statins significantly reduced the risk of developing colonic 
cancer, where this effect was more pronounced the longer 
such therapy had been adopted [17].
A large group of subjects suffering from colonic cancer 
(n > 18,000) were investigated in a Danish study during 
1995–2007, which found that the overall risk of death, as well 
as the risk of death from cancer became reduced through 
using inhibitors of HMG-CoA reductase [18]. A study by 
Lakha et al., however suggested that statin therapy lowers 
the risk of colonic cancer but has no effect on mortality in 
those patients diagnosed with cancer [19]. Nevertheless, 
a study by Cardwell et al. monitored 7,657 subjects with 
colonic cancer for over 9 years, which at the end found that 
the cancer mortality risk had decreased upon taking HMG-
CoA inhibitors, with risk reductions being all the greater 
the longer such therapy had been undergone [20]. These 
conclusions were however challenged by Sendur et al., who 
pointed out that the analysis took no account of the ox-
aliplatin therapy regimen that had been introduced over 
the study period and, which of itself, most likely improved 
survival outcomes in the colorectal cancer patients receiv-
ing this treatment – regardless of the statin therapy [21].
A meta-analysis was undertaken in 2013 by Liu et al. 
which critically reviewed 42 such studies and ultimately 
concluded that, indeed, statins significantly reduced the 
Table I. Characteristics of statins





Lovastatin Naturally occuring Bowel wall and liver (CYP3A4) Faecal 83 Yes Yes I
Renal 10
Pravastatin Naturally occuring Stomach and cell cytoplasm (sulphonation) Faecal 71 No No I
Renal 20
Simvastatin Semi-synthetic Bowel wall and liver (CYP3A4) Faecal 58 Yes Yes II
Renal 13
Atorvastatin Synthetic Bowel wall and liver (CYP3A4) Faecal 70 No Yes IV
Renal 2
Cerivastatin Synthetic Bowel wall and liver (CYP3A4,CYP2C8) Faecal 70 No Yes IV
Renal 24
Fluvastatin Synthetic Bowel wall and liver (CYP2C9) Faecal 90 No No III
Renal 6
Rosuvastatin Synthetic Bowel wall and liver (CYP2C9, CYP2C19) Faecal 90 No Little IV
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risk of developing colonic cancer of the colon [22]. An earlier 
meta-analysis from 2007 on 18 statin trials, encompassing 
in total 1.5 million patients, conducted by Bonovas et al. 
confirmed the link between using statins with the reduced 
risk of colorectal cancer in case-control studies, but not, 
however, in randomized clinical trials nor through cohort 
studies [23].
Other studies have also been less promising, which 
amongst various factors, found that mortality risks were 
not reduced in patients that had undergone statin treat-
ment lasting more than five years [24–26]. These disparities 
are most probably due to the heterogeneity of the groups 
studied and the extensive effect of confounding factors, 
such as the coexistence of other diseases, polypharmacy, 
lifestyle, age and family history which often in themselves 
constitute independent risk factors for colorectal cancer.
Experimental studies
Numerous experimental studies have traced the ef-
fect of statins on the development of colorectal cancer 
through investigating individual components of local-
ised growth processes and invasiveness. Statins regulate 
cellular proliferation and cell growth as demonstrated 
by studies on murine and human cell lines of colorectal 
cancer. When cell culture media contain statins, decreases 
in both cell viability and their proliferative potential are 
observed [27, 28]. Furthermore, the presence of statins in 
culture media enhances apoptosis, probably by regulat-
ing bcl-2 transcription and activating pro-apoptotic Bax 
protein, as confirmed by studies on cell lines of human 
colonic carcinomas (HT29) [28–30]. However, Al-Haidari et 
al. demonstrated in these same cell lines, after induction 
with CCL17, that simvastatin significantly affects the ability 
Figure 1. The mevalonate pathway and its inhibitors
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of these cells to migrate without affecting their prolifera-
tion and apoptosis [31].
Colonic cancer tumours are part of those whose growth 
are stimulated, amongst others, through activation of IGF 
receptors. The occurrence of insulin resistance with the ac-
companying high levels of IGFs in obese patients are one of 
the causes of an increased risk of colorectal cancer for this 
group. McCarty et al. in 2001 demonstrated that inhibitors 
of HMG-CoA reductase are responsible for decreased IGF-1 
receptors on the surface of colonic cancer cells [32, 33]. This 
effect may significantly limit the tumour’s growth potential 
because IGFs are in fact one of the most potent growth 
factors found in the human body. The effect of statins on 
subsequent stages of tumourigenesis and on tumour cell 
invasion of adjacent tissues has also been confirmed. This 
process is dependent, amongst others, on the activity of 
matrix metalloproteinases (MMPs) which, by degrading the 
matrix structure, facilitates tumour invasion of further areas. 
Metalloproteinases are actively produced by cancer cells as 
well as by stromal cells, which potentiate tumour invasion 
of the microenvironment [34]. Furthermore, MMPs regulate 
the bioavailability of other proteins, including adamalysins, 
that according to recent studies, also play a key role in tu-
mourigenesis by activating signalling pathways associated 
with growth factors IGF, EGF, VEGF and likewise the TNF-α 
pathway [ 34].
Experiments on human cell lines of colonic cancer dem-
onstrate that lovastatin has the potential to inhibit activities 
of MMP-1, 2, 3 and 9, whereas simvastatin does so only for 
MMP-9 [35–37]. Statins can also limit cell migration as well 
as the formation of distant metastases by restricting adhe-
sion of tumour cells to capillary walls; this being one of the 
intermediate stages of the metastatic cascade. A study by Al-
Haidari et al. [31] confirmed such cell migration restrictions 
on the HR-29 cell line. The effects of statins on cell cultures 
are a decrease in the expression of adhesion molecules 
ICAM-1, PECAM, VCAM-1 and 1-selectin on cell surfaces, 
thereby making difficult/confounding both adhesion to 
vascular endothelial cells and distant migration [38, 39].
Finally, another stage of tumour progression affected 
by HMG-CoA inhibitors is neoangiogenesis, which forms 
an essential part of further tumour growth at the point 
at which the tumour attains a size where further growth 
becomes untenable if only simple diffusion is relied upon 
for supplying oxygen and nutrients. Statins inhibit vascular 
proliferation through decreasing the expression of growth 
factors VEGF and PDGF which have been confirmed by stud-
ies on lovastatin, simvastatin and cerivastatin [33, 40].
In addition, Japanese studies have demonstrated that 
when pitavastatin was given to a studied Min-mouse strain, 
the numbers of polyps in the large intestine become sig-
nificantly reduced together with a decreased expression of 
inflammatory cytokines in the colonic mucosa – suggest-
ing that statins possess a high potential for prophylactic 
action [41].
Conclusions
The state of affairs as presented above, describes what 
is currently known from experimental and epidemiological 
studies. These have pinpointed inhibitors of HMG-CoA to 
be considered amongst those substances having potential 
anti-tumour effects in colorectal cancer. It should however 
be realised that a major proportion of the experimental 
studies have been performed on cell lines or animal models, 
where the beneficial effects so demonstrated have not been 
necessarily translated to, or confirmed by epidemiological 
studies on large patient groups. Nonetheless, there are some 
hopeful signs that statins are now more frequently being 
considered as having a role in adjunctive therapies used in 
oncology, because of their potentially synergistic effects 
with anticancer drugs, such as 5-FU or doxorubicin, that 
reduce the chemo-resistance of cancer cells to cytostatic 
treatments [42]. When cell lines of colorectal cancer are 
incubated with atorvastatin, the subsequently appearing 
drug resistance to doxorubicin is absent, when compared 
to cancer cell lines grown without statins [43].
But still a number of open questions remain, which can 
only be answered by wide-ranging and detailed clinical 
studies. Because most of the existing studies hitherto have 
covered rather short durations of applied statin therapy, it 
is thereby important that they are complemented by stud-
ies on patients that have been taking HMG-CoA reductase 
inhibitors for long periods of time.
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